An intriguing finding of our studies was that MTR OralGem treatment enhanced antitumor immunity in a syngeneic lung cancer model by decreasing the percentages of CD4+Foxp3+ Treg cells and increasing CD3+CD4+ and CD3+CD8+ T effector cell infiltration in the TME. The gene discussed is FOXP3; the disease is lung cancer.